Bladder Cancer VL

Enhanced Recovery After Surgery (ERAS) for Radical Cystectomy: History, Rationale and Programmatic Implementation - Thomas Guzzo

Details
(Length of Discussion: 34 min) Dr. Thomas Guzzo starts his discussion by dialing back to 1997 to share with listeners the beginning of Enhanced Recovery After Surgery (ERAS) and the work of Dr. Kelhlet from Denmark who described multifactorial surgical stress responses such as the pathogenesis of postoperative sleep disturbances as multifactorial, and includes different neural stimulus (surgical s...

Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde

Details
(Length of Discussion - 9 min) Dr. Alicia Morgans discusses with Dr. Guru Sonpavde the advances in the field of bladder cancer in regards to immunotherapy treatment approaches and recent ongoing clinical trials. Dr. Morgans refers to these treatment options and new studies as bringing a freshness to a desert like climate which has been bladder cancer treatment over the past several decades. Dr. So...

Review of SIU-ICUD Joint Consultation on Badder Cancer - Thomas Keane

Details
Dr. Thomas Keane reviews recent data presented at the SIU-ICUD Joint Consultation on Bladder Cancer 2017 conference focusing on a number of presentation highlights. The main purpose of the meeting was for each of the chapter editors to present work from their groups, specifically providing any significant updates from the 2012 edition. They included the level of evidence and grade of recommendatio...

Advanced Bladder Cancer Management: Immunotherapy - Interview with Arjun Balar

Details
Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence, an Interview with Alicia Morgans and Arjun Balar Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Discussion: 13 min) Alicia Morgans, MD interviews Dr. Arjun Balar on his take home message on Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence, the t...

Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence - Arjun Balar

Details
Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence Presentation from the 2017 Annual LUGPA meeting in Chicago, IL (Length of presentation: 28 min) Arjun Balar, MD discusses the need for cancer immunotherapy, a biologically-driven form of therapy where the body’s immune system is used to fight cancer. In the past, Cisplatin/Methotrexate was the therapy of choice...

'To Robot or Not to Robot’: Radical Cystectomy for Muscle-Invasive Bladder Cancer- Bernard Bochner

Details
'To Robot or Not to Robot’: Radical Cystectomy for MIBC - Bernard Bochner (Length of discussion - 33 minutes) Dr. Ashish Kamat welcomes Dr. Bernard Bochner in a discussion on robotic vs open radical cystectomy surgical options as a new standard of practice in the management of muscle-invasive bladder cancer (MIBC). He presents several studies and analyzes results with key oncologic outcomes in the...

Myths and Mysteries Surrounding Adjuvant Therapy for NMIBC - Ashish Kamat

Details
(Length of lecture - 32 minutes) Ashish Kamat, MD presents on the myths and mysteries surrounding adjuvant therapy for non-muscle invasive bladder cancer (NMIBC). Dr. Kamat explains the non-homogenous characteristics and lack of uniformity in risk factors of NMIBC. He discusses study results of BCG contribution to reduction in progression of NMIBC when maintenance is used. For reference, PDF of sl...

Perspectives on Clinical Trial Design in NMIBC - Ashish Kamat

Details
(Length of discussion - 7 minutes) E. David Crawford hosts a discussion with Ashish Kamat on perspectives in clinical trials in non-muscle invasive bladder cancer (NMIBC). He highlights some challenges FDA approved drugs face from trial to trial depending on the grading system used. He reflects on the difficulty that arrises when comparing across different studies because of various grading system...

The Conundrum of Recurrent Low Grade Tumors - James McKiernan

Details
(Length of discussion ~ 23 minutes) Dr. James McKiernan discussion the issues and dilemmas in low grade bladder cancer and the challenges that are being faced with treating recurrent low-grade bladder tumors. He focuses his presentation on lower risk tumors that recur posing major burden on patients and the health care system. Patients that fall into the low stage and low grade Ta category of papi...

Immunotherapy of Advanced Bladder Cancer - Daniel Petrylak

Details
(Length of lecture - 38 minutes) Daniel Petrylak, MD presents response rates and anti-tumor activity of checkpoint inhibition therapy in patients with advanced urothelial carcinoma and immunotherapy as initial therapy in cisplatin-ineligible patients and in patients with cisplatin pretreated disease. Dr. Petrylak discusses trials that are on-going to explore immunotherapy based combinations and th...